David MacFarlane - Titan Pharmaceuticals Independent Director

TTNP Stock  USD 7.16  0.22  2.98%   

Director

Dr. M. David MacFarlane, Ph.D., is Independent Director of Titan Pharmaceuticals, Inc. David MacFarlane, Ph.D. served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. Prior to joining Genentech, Inc., he served in various positions with Glaxo Inc., last as Vice President of Regulatory Affairs. Based on Dr. MacFarlanes management experience in the pharmaceutical industry, particularly in the area of clinical and regulatory affairs, our Board believes that Dr. MacFarlane has the appropriate set of skills to serve as a member of the Board. since 2002.
Age 73
Tenure 22 years
Professional MarksCFA
Address 400 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Phone650 244 4990
Webhttps://www.titanpharm.com

Titan Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.6111) % which means that it has lost $0.6111 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0554) %, meaning that it created substantial loss on money invested by shareholders. Titan Pharmaceuticals' management efficiency ratios could be used to measure how well Titan Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/29/2024, Return On Capital Employed is likely to grow to -7.83. In addition to that, Return On Assets is likely to grow to -2.74. At this time, Titan Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 03/29/2024, Non Current Liabilities Other is likely to grow to about 1 M, while Liabilities And Stockholders Equity is likely to drop slightly above 3.5 M.
The company currently holds 187 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Titan Pharmaceuticals has a current ratio of 3.0, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Titan Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Titan Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Titan Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Titan to invest in growth at high rates of return. When we think about Titan Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Lian GoldsteinShagrir Group Vehicle
42
Larry SwitzerAmerican Axle Manufacturing
68
Bill GossmanNLIGHT Inc
56
Herbert ParkerAmerican Axle Manufacturing
63
James McCaslinAmerican Axle Manufacturing
72
Elizabeth ChappellAmerican Axle Manufacturing
63
Gail HamiltonArrow Electronics
71
Philip AshermanArrow Electronics
67
Laurel KrzeminskiArrow Electronics
66
David AndersonModine Manufacturing
71
Shai CohenShagrir Group Vehicle
50
Dana YosefShagrir Group Vehicle
39
Steven HantlerAmerican Axle Manufacturing
62
John SmithAmerican Axle Manufacturing
70
Stephen PatrickArrow Electronics
71
Sandra PierceAmerican Axle Manufacturing
62
Jason ParsonsAmerican Axle Manufacturing
N/A
David BillsModine Manufacturing
59
Gary LockeNLIGHT Inc
68
Suresh GarimellaModine Manufacturing
56
Kevin PennAmerican Axle Manufacturing
N/A
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. The company was incorporated in 1992 and is based in South San Francisco, California. Titan Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people. Titan Pharmaceuticals (TTNP) is traded on NASDAQ Exchange in USA. It is located in 400 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 4 people. Titan Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Titan Pharmaceuticals Leadership Team

Elected by the shareholders, the Titan Pharmaceuticals' board of directors comprises two types of representatives: Titan Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Titan. The board's role is to monitor Titan Pharmaceuticals' management team and ensure that shareholders' interests are well served. Titan Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Titan Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Rubin, Executive Chairman of the Board
Rajinder Kumar, Director
Brian Crowley, Senior Administration
Sunil Bhonsle, President, Secretary and Director
James McNab, Director
Federico Recli, Director
David MacFarlane, Independent Director
Joseph Akers, Director
Eurelio Cavalier, Independent Director
Marc MD, Ex Director
David Lazar, Principal Officer
Scott Smith, Director
Joe Schrei, Executive Operations
Katherine BeebeDeVarney, COO President
Ley Smith, Independent Director
Dane Hallberg, Executive Vice President and Chief Commercial Officer
Jennifer Kiernan, Executive Coordinator
Victor Bauer, Independent Director
Seghi Recli, Lead Director
Mike Fritz, National Director

Titan Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Titan Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Titan Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Titan Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Titan Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Titan Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Titan Stock analysis

When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Stocks Directory
Find actively traded stocks across global markets
CEOs Directory
Screen CEOs from public companies around the world
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Is Titan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Titan Pharmaceuticals. If investors know Titan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Titan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.20)
Revenue Per Share
0.409
Quarterly Revenue Growth
(0.96)
Return On Assets
(0.61)
Return On Equity
(1.06)
The market value of Titan Pharmaceuticals is measured differently than its book value, which is the value of Titan that is recorded on the company's balance sheet. Investors also form their own opinion of Titan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Titan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Titan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Titan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Titan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Titan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Titan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.